Title : Antibacterial activity of dihydroanthracene disulfonic acid derivative against multiresistant mixed bacterial infection
Abstract:
This study presents the in vivo and in vitro activity of dihydroanthracene disulfonic acid derivative, a new preparation with patent DE102004003030 A1. The in vivo study was performed in a 61-year-old patient of the UHC “Mother Theresa” Tirana with colon resection and colostomy for colon adenocarcinoma, verified by biopsy examination, complicated with Necrotitizing Fasciitis. 24 incisions were performed in the dorsal part from which were observed bad odor pus and presence of necrotic tissue. The standard local treatment and general treatment with Cefazolini, Metronidazole, Gentamycini IV, in the first two weeks didn´t result effective. Microbiological analysis resulted in mixed flora with streptococci, enterobacteria, bacterium coli, proteus pseudomonas and anaerobes resistant to ampicilline, piperacillin, ceftazidime, imipenem and moderately sensitive to cotrimoxazole and azithromycin. Biochemical analyzes showed anemia and hepatic damage. After multidisciplinary consultation antibiotics were dropped. After the patient consent, the new preparation was used topically as 20% solution and orally 2 g/twice daily. The treatment was well tolerated. The patient's temperature dropped and elimination of the bad odor and reduced secretion were observed. Healing of the wounds lasted 3 months. in vitro evaluation of the new preparation on resistant strains isolated from another patient with Necrotizing Fasciitis were conducted, a 10% solution preparation showed antimicrobial effect equivalent to in vitro Imipenem (MIC<=0.25), Colistin (MIC<=0.5). The positive result in this severe mix flora infection with multiresistant strains indicates the value of the preparation. Further studies are needed to evaluate the full pharmacological activity.
